Roche’s Nivegacetor Turns Off the Toxic Aβ Tap in Paisa Kindred (2026)

Imagine a world where we could simply shut off the faucet of toxic brain plaque buildup in Alzheimer's disease – not just scraping away the mess, but preventing it from forming in the first place. That's the tantalizing promise of Roche's Nivegacetor, a groundbreaking drug tackling the root cause in a rare hereditary group. But here's where it gets controversial: What if this approach, which avoids the pitfalls of past failures, could revolutionize treatment for everyone, or might it stir up debates about genetic targeting versus broader therapies? Stick around as we dive into the latest findings from a pivotal study that might just change the Alzheimer's landscape forever.

Dated December 19, 2025

While anti-amyloid antibodies excel at removing built-up plaque in the brain, imagine flipping the switch to prevent that harmful buildup altogether. That's the innovative strategy behind γ-secretase modulators. These compact molecular drugs latch onto a protein embedded in cell membranes called γ-secretase and guide it to cut the amyloid precursor protein (APP) into shorter fragments of Aβ peptides – versions that resist clumping together dangerously. Presenting at this year's CTAD conference, from December 1-4 in San Diego, Rosanna Tortelli from Hoffmann-La Roche in Basel, Switzerland, unveiled fresh insights from a Phase 1b trial of nivegacetor (detailed at https://www.alzforum.org/therapeutics/nivegacetor), the company's advanced second-generation GSM, in individuals with the PSEN1 E280A mutation (explored at https://www.alzforum.org/mutations/psen1-e280a-paisa). This genetic variant disrupts APP's interaction with presenilin, the enzyme's active center, leading to an excess of harmful Aβ42 molecules.

In those carrying the PSEN1 E280A mutation, nivegacetor redirected APP breakdown to produce shorter, less sticky Aβ peptides.
The peptide profile adjusted in a similar manner in blood plasma and cerebrospinal fluid (CSF) from both mutation carriers and non-carriers.
Phase 2 trials for typical Alzheimer's are underway, with a combined study using donanemab in hereditary cases on the horizon.

“This marks the initial human evidence that nivegacetor influences a faulty γ-secretase similarly to its normal version,” Tortelli explained to Alzforum.

Back in 2021, Roche initiated a Phase 1 trial of nivegacetor – also known as RG6289 – involving 127 healthy participants, and the results were striking: it favored the creation of Aβ37 and Aβ38 while nearly wiping out problematic Aβ40 and Aβ42 (from November 2023 conference updates at https://www.alzforum.org/news/conference-coverage/second-generation-g-secretase-modulator-heads-phase-2; and the abstract at https://medically.gene.com/global/en/unrestricted/neuroscience/CTAD-2023/ctad-2023-poster-portron-rg6289-a-new--secretase-modul.html). Crucially, it didn't tamper with γ-secretase's handling of other targets, sidestepping the issues that derailed earlier γ-secretase inhibitors (as seen in December 2012 news at https://www.alzforum.org/news/research-news/drug-company-halts-development-g-secretase-inhibitor-avagacestat; April 2011 conference reports at https://www.alzforum.org/news/conference-coverage/barcelona-allosteric-g-modulation-moves-toward-clinic; August 2010 updates at https://www.alzforum.org/news/research-news/lilly-halts-identity-trials-patients-worsen-secretase-inhibitor; and July 2025 findings at https://www.alzforum.org/news/research-news/ai-decodes-hidden-features-g-secretase-substrates-finds-160-new-ones).

These promising outcomes propelled nivegacetor to Phase 2 in 2024, positioning it as the pioneer – and so far, the sole – drug in its category to reach this milestone. “Companies like BMS, Pfizer, and smaller biotech firms attempted similar approaches, but early-stage safety concerns halted their progress,” noted Robert Alexander, a co-author and trial investigator at Banner Alzheimer’s Institute, in an interview with Alzforum. A current study, slated to conclude by late 2026 (presented at AD/PD 2024 at https://medically.roche.com/content/dam/pdmahub/restricted/neurology/adpd-2024/ADPD-2024-presentation-tortelli-a-phase-IIa-study.pdf; and listed on clinicaltrials.gov at https://clinicaltrials.gov/study/NCT06402838), has recruited 256 individuals between 60 and 85 years old with confirmed brain amyloid via PET scans, spanning from cognitively intact to those with mild impairment.

Roche’s Nivegacetor Turns Off the Toxic Aβ Tap in Paisa Kindred (2026)

References